Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary

• Coherus Oncology Inc CHRS.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of five analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -33 cents to -31 cents per share.

• Revenue fell 84.2% to $10.25 million from a year ago; analysts expected $10.14 million.

• Coherus Oncology Inc's reported EPS for the quarter was $2.57​.

• The company reported quarterly net income of $297.77 million.

• Coherus Oncology Inc shares had risen by 25.2% this quarter and lost 33.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 34.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 86.4% above its last closing price of $0.88

This summary was machine generated from LSEG data August 8 at 04:44 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)